[Clinical studies of dibekacin intravenous challenge on respiratory tract infections (author's transl)].
Dibekacin was used for the treatment of 5 patients with bacterial respiratory tract infections (4 cases of Ps. aeruginosa and 1 case of S. marcescens) intravenously. Serum levels of DKB was observed by the method of enzyme immunoassay (EIA) and bioassay and no differentiation was observed between EIA and bioassay. Four cases of Ps. aeruginosa and 1 case of S. marcescens were all disappeared in 5 or 7 days of administration. No side effects were observed. The results obtained in this study indicate that DKB intravenous challenge might become one of the important method on respiratory tract infections.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000378:metabolism / Q000627:therapeutic use*; D003982:Dibekacin / Q000008:administration & dosage* / Q000378:metabolism; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007263:Infusions, Parenteral; D007612:Kanamycin / Q000031:analogs & derivatives*; D008297:Male; D008875:Middle Aged; D011552:Pseudomonas Infections / Q000188:drug therapy; D012141:Respiratory Tract Infections / Q000188:drug therapy* / Q000382:microbiology; D013183:Sputum / Q000378:metabolism
D000900:Anti-Bacterial Agents; D003982:Dibekacin; D007612:Kanamycin